1. Home
  2. AGD vs LUNG Comparison

AGD vs LUNG Comparison

Compare AGD & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Global Dynamic Dividend Fund of Beneficial Interest

AGD

abrdn Global Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$11.44

Market Cap

288.1M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.50

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGD
LUNG
Founded
2006
1995
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.1M
63.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AGD
LUNG
Price
$11.44
$2.50
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
61.2K
1.1M
Earning Date
01-01-0001
11-12-2025
Dividend Yield
8.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.59
52 Week Low
$8.20
$1.31
52 Week High
$9.78
$9.37

Technical Indicators

Market Signals
Indicator
AGD
LUNG
Relative Strength Index (RSI) 47.28 68.25
Support Level $11.33 $1.96
Resistance Level $11.52 $2.66
Average True Range (ATR) 0.16 0.19
MACD 0.02 0.08
Stochastic Oscillator 41.03 84.40

Price Performance

Historical Comparison
AGD
LUNG

About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest

Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors among others.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: